Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Nicotinamide for inducing antimicrobial peptide production

A technology of nicotinamide and its application, which is applied in the direction of antibacterial drugs, drug combination, drug delivery, etc., and can solve the problem of impaired ability to clear Staphylococcus aureus infection

Pending Publication Date: 2022-01-11
UNILEVER IP HLDG BV
View PDF5 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Specifically, it has been shown that mice are severely impaired in their ability to clear S. aureus infection in the absence of functional C / EBPe

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Nicotinamide for inducing antimicrobial peptide production
  • Nicotinamide for inducing antimicrobial peptide production

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1 to 6

[0035] Examples 1 to 6: Demonstration that nicotinamide induces LL-37 gene expression but does not alter psoriasin expression Example of

[0036] The following samples as shown in Table 1 were prepared in order to measure their effects on psoriasis expression and expressed psoriasis AMP (LL-37).

[0037] Table 1

[0038] Example sample 1 Controls for LL-37 gene expression 2 Positive control LPS (25↘g / ml) for LL-37 gene expression 3 Nicotinamide (1.22mg / ml) for LL-37 gene expression 4 Controls for psoriasis gene expression 5 Positive control LPS (25↘g / ml) for psoriasis gene expression 6 Niacinamide (1.22mg / ml) for psoriasis gene expression

[0039] .

[0040] Materials and procedures used to measure the expression of each gene are given below.

[0041] Material

[0042] Normal Human Neonatal Epidermal Primary Keratinocytes (NHEK), Keratinocyte Growth Medium (KGM) and Growth Supplements, Antibiotics (Penicillin and Stre...

Embodiment 7 to 12

[0055] Examples 7 to 12: In vivo experiments using skin lotions containing niacinamide to demonstrate the Secretion of dermatoxin and LL-37 To confirm the findings from in vitro experiments, the effects of nicotinamide were tested in vivo on healthy human volunteers. Volunteers were asked to apply lotion with and without niacinamide (3%) twice daily on their forearms. After 7 days of application, spots were extracted in PBS and ELISA was performed to detect psoriasis and LL-37AMP.

[0056] In vivo study procedure

[0057] E. coli culture preparation

[0058] A glycerol stock of E. coli (10536) was inoculated in 30 ml TSB medium and the culture was incubated overnight at 37°C in a shaking incubator. Overnight cultures were subcultured on TSA slants and incubated overnight at 37°C before storing the slants at 4°C (slants were freshly prepared once 15 days old).

[0059] E. coli cultures from slants were subcultured on TSA plates and incubated overnight at 37°C. Plate...

Embodiment 13

[0088] Example 13: Experiments to determine the type and amount of antimicrobial peptide (AMP) secreted by nicotinamide induction The following procedure was used to determine AMP induced by nicotinamide on keratinocytes.

[0089] 1. Seed primary keratinocytes in a 12-well plate with 1 ml KGM complete medium. (60,000 cells / well seeded at passage 4).

[0090] 2. Place the plate in CO 2 Incubate for 48 hours in an incubator.

[0091] 3. After 48 hours of incubation, cells were treated in duplicate wells with and without nicotinamide at a concentration of 1 mg / ml (fresh medium was used for treatment).

[0092] 4. After 72 hours of incubation, the cell culture supernatants were transferred to 1.5 ml microcentrifuge tubes respectively.

[0093] 5. The sample was then passed through a 20 kDa cut-off filter to remove high molecular weight proteins.

[0094] 6. Transfer the eluted sample containing <20kDa protein to a 15ml sterile centrifuge tube.

[0095] 7. Subsequently, add ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to a novel use of nicotinamide for triggering AMP (antimicrobial peptide) production on the skin. This can be applied to improve the immunity of the skin, scalp and oral cavity against microbial attack.

Description

[0001] This application is a divisional application of an invention patent application. The application date of the parent case is May 12, 2014, the application number is 201480078798.X (PCT / EP2014 / 059590), and the invention name is "Used to induce antimicrobial Peptide-generated nicotinamide". [0002] field of invention [0003] The present invention relates to the novel use of niacinamide for triggering AMP (antimicrobial peptide) production on the skin. This could be applied to improve the immunity of the skin, scalp and mouth against microbial attack. [0004] Background of the invention [0005] The skin is the body's first line of defense against invading pathogens such as viruses and bacteria. As the primary defense organ, skin tissue is always in constant contact with the environment and must therefore face and address threats and challenges from invading pathogens. Exposed skin surfaces are not only challenged by pathogenic foreign bacteria, but also remain in cont...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K8/67A61Q17/00A61Q5/00A61Q11/00A61P31/04A61P17/00
CPCA61K8/675A61Q17/005A61K31/455A61K9/0014A61Q5/00A61Q11/00A61P17/00A61P31/04A61P37/02
Inventor A·马祖姆达M·S·马塔帕蒂B·帕兰伊萨米R·萨姆帕特库马J·K·蒂瓦里
Owner UNILEVER IP HLDG BV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com